The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• The c-Jun NH(2)-terminal kinase (JNK) signaling pathway is linked to various diseases, including cancer.
• The specific roles of different JNK proteins in human cancer development remain largely unknown.

Purpose of the Study:

• To investigate the distinct contributions of JNK1 and JNK2 in human squamous cell carcinoma (SCC) pathogenesis.
• To explore the therapeutic potential of targeting JNK2 in SCC.

Main Methods:

• Analysis of JNK2 activation in human SCC samples.
• Pharmacological and genetic inhibition of JNK2 in SCC cells.
• Investigation of JNK2's interaction with oncogenic Ras in primary human epidermal cells.
• Assessment of JNK2's impact on cell senescence, growth arrest, p16 expression, NF-kappaB activation, and Ras-induced glycolysis.

Main Results:

• JNK2 is activated in over 70% of human SCC samples.
• JNK2 inhibition, via pharmacological or genetic means, reduces SCC cell tumorigenesis.
• JNK2, unlike JNK1, can cooperate with oncogenic Ras to transform epidermal cells into SCC.
• JNK2 suppresses Ras-induced senescence and growth arrest by downregulating p16 and NF-kappaB.
• JNK2 and phosphoinositide 3-kinase are crucial for Ras-induced glycolysis, supporting cancer cell growth.

Conclusions:

• JNK2 plays a critical role in promoting SCC tumorigenesis by collaborating with oncogenes like Ras at multiple molecular levels.
• JNK2's functions in preventing senescence and promoting glycolysis make it a promising therapeutic target for SCC treatment.